Method and system for determining the validity of test results of immune in vitro diagnostic reagents
By adding elution steps and calculating the percentage of elution in the immune detection process, the problem of difficult to determine the effectiveness of immune in vitro diagnostic reagent detection results is solved, and the accurate identification and misjudgment of abnormal results is achieved, which improves the improvement of Accuracy of the test results.
Patent Information
- Application Number
- CN202210653120.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-06-09
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2042-06-09
AI Technical Summary
There is a problem that the effectiveness of a single test result is difficult to determine in the existing immune in vitro diagnostic reagent test results, especially when the sample has interference such as heterophilic antibodies, human anti-mouse antibodies or non-specific binding, ordinary quality control methods cannot be An abnormal result was found, resulting in false positives.
By adding elution steps to the immune detection process, using an eluent to elute the detection probe, and determining the validity of the detection result by calculating the elution percentage. If the elution percentage is within the threshold range, the result is determined to be normal. Otherwise, it is an exception.
Without increasing costs, individual abnormal results that cannot be avoided in immune detection can be easily identified, misjudgment can be avoided, and the accuracy and accuracy of the detection results can be improved.
Smart Images

Figure CN114994302B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical devices, and in particular to a method and system for determining the validity of detection results of immune in vitro diagnostic reagents. Background Art
[0002] Immunological in vitro diagnostic reagents are a type of detection method based on the specific reaction of antigens and antibodies. They can amplify and display the detected signals using isotopes, enzymes, fluorescent substances, chemiluminescent substances, etc. At present, the main immunoassays used in the clinical field include fluorescent immunoassay, radioimmunoassay (RIA), enzyme-linked immunosorbent assay (EIA), chemiluminescence immunoassay (CLIA), etc.
[0003] Due to the differences in detection conditions and analytes, detection methods can be divided into double antibody sandwich method, competitive method, indirect method, capture method, etc. Taking the double antibody sandwich method as an example, the above methodologies are all based on coating a capture antibody on a certain solid phase matrix, using another labeled antibody as a detection antibody to form an antibody-antigen-antibody complex with the antigen substance in the sample, and detecting the result or content of the unknown sample through the amount of labeled antibodies, fluorescence, absorbance, luminescence value and other physical signal means.
[0004] In this type of immunoassay results, a common problem is the validity of a single test result. Although each methodology will control the controllability of the system test results through calibration or quality control to determine the validity of the test results, it is all based on whether the overall test system is normal. If there are some unknown or rare special reasons in the individual sample itself (such as heterophilic antibodies, human anti-mouse antibodies (HAMA), non-specific binding, exogenous or endogenous interference, etc.), there is a certain probability that the test results will be abnormal. At this time, ordinary quality control methods cannot detect such abnormal results, so errors occur in the results. Summary of the invention
[0005] The purpose of the present invention is to solve the above problems existing in the prior art and to provide a method and system for determining the validity of the test results of immune in vitro diagnostic reagents.
[0006] The purpose of the present invention is achieved through the following technical solutions:
[0007] The method for determining the validity of the test results of immune in vitro diagnostic reagents includes the following steps:
[0008] S1, after obtaining the first detection result of the immunoassay, eluting the detection probe after the immunoassay with an elution solution;
[0009] S2, immersing the eluted detection probe into a reading hole, reading the result through a reading device, and obtaining a second detection result;
[0010] S3, calculating the elution percentage according to the first test result and the second test result;
[0011] S4, determining whether the elution percentage is within a threshold range, if so, determining that the test result of the immune in vitro diagnostic reagent is normal; otherwise, determining that the test result of the immune in vitro diagnostic reagent is abnormal.
[0012] Preferably, the eluent is at least one of PBST buffer, TBST buffer, MES buffer, and glycine buffer.
[0013] Preferably, the pH value of the eluent is between 2 and 8.
[0014] Preferably, the detection probe is eluted in the elution solution for a period of 30 to 180 seconds.
[0015] Preferably, the elution percentage P is calculated according to the following formula:
[0016] P=(Q1-Q2) / Q1%
[0017] Among them, Q1 is the first detection result, and Q2 is the second detection result.
[0018] Preferably, the threshold range is between 24.9% and 44.3%.
[0019] Preferably, the first detection result is obtained according to the following steps:
[0020] S01, preparing the detection probe, cleaning solution, biotinylated detection antibody, streptavidin-cyanine dye 5 and detection sample required for immunoassay;
[0021] S02, cleaning the detection probe with a cleaning solution;
[0022] S03, after cleaning, immersing the detection probe into the detection sample to react for a first target time;
[0023] S04, taking out the detection probe from the detection sample and cleaning it with a cleaning solution;
[0024] S05, after washing, immersing the detection probe in the biotinylated detection antibody to react for a second target time;
[0025] S06, removing the detection probe from the biotinylated detection antibody and washing it with a washing solution;
[0026] S07, after washing, immersing the detection probe in streptavidin-cyanine dye 5 to react for a third target time;
[0027] S08, taking out the detection probe from the streptavidin-cyanine dye 5 and washing it with a washing solution;
[0028] S09, after cleaning, placing the detection probe into the reading hole to read and obtain the first detection result.
[0029] Preferably, the detection probe is treated with a moisture-proof liquid during the coating process.
[0030] The method for determining the validity of the test results of immune in vitro diagnostic reagents includes the following steps:
[0031] S10, controlling the mobile actuator to drive the detection probe to perform immune detection according to a conventional immune detection process and obtain a first detection result;
[0032] S20, controlling the mobile actuator to immerse the detection probe processed in S10 into the eluent for elution;
[0033] S30, controlling the moving actuator to move the eluted detection probe to the reading hole, controlling the reading device to read, and obtaining a second detection result;
[0034] S40, determining an elution percentage according to the second detection result and the first detection result;
[0035] S50, determining whether the elution percentage is within a preset range; if so, determining that the test result of the immunological in vitro diagnostic reagent is normal; otherwise, determining that the test result of the immunological in vitro diagnostic reagent is abnormal.
[0036] The validity determination system of the test results of immunological in vitro diagnostic reagents includes
[0037] An immune detection unit, used for controlling the mobile actuator to drive the detection probe to perform immune detection according to a conventional immune detection method and obtain a first detection result;
[0038] An elution unit is used to control the mobile actuator to immerse the detection probe processed by the immunodetection unit into the elution solution for elution;
[0039] A re-reading unit, used to control the moving actuator to move the eluted detection probe to the reading hole, control the reading device to read, and obtain a second detection result;
[0040] a calculation unit, configured to determine an elution percentage according to the second detection result and the first detection result;
[0041] The judging unit is used to judge whether the elution percentage is within a preset range; if so, it is determined that the test result of the immune in vitro diagnostic reagent is normal; otherwise, it is determined that the test result of the immune in vitro diagnostic reagent is abnormal.
[0042] The advantages of the technical solution of the present invention are mainly reflected in:
[0043] The present invention adds an elution process to the original immunoassay process, and quantitatively determines the validity of the test result by calculating the elution percentage of the test, so that individual abnormal results that are inevitable in immunoassays can be easily identified without increasing costs, thereby avoiding false positives caused by heterophilic antibodies, human anti-mouse antibodies, nonspecific binding, exogenous or endogenous interference, etc.
[0044] This scheme can ensure the accuracy of the final confirmation and avoid misjudgment through precise design of elution time and threshold.
[0045] The test probe of this scheme is surface-modified by a silane coupling agent and treated with a moisture-proof liquid during the coating process. After surface modification and moisture-proof treatment, the resistance time of the antibody on the surface of the test probe to the humid environment can be effectively prolonged, so that the active life of the antibody is significantly extended, and the detection effectiveness during immunoassay is easily guaranteed. BRIEF DESCRIPTION OF THE DRAWINGS
[0046] Figure 1 It is a schematic diagram of the principle of performing immunoassay reaction reading on the detection probe in the reading hole in the present invention. DETAILED DESCRIPTION
[0047] The purpose, advantages and features of the present invention will be illustrated and explained by the non-limiting description of the following preferred embodiments. These embodiments are only typical examples of the application of the technical solution of the present invention, and any technical solution formed by equivalent replacement or equivalent transformation falls within the scope of protection claimed by the present invention.
[0048] In the description of the scheme, it should be noted that the terms "center", "upper", "lower", "left", "right", "front", "back", "vertical", "purification level", "inside", "outside" and the like indicate positions or positional relationships based on the positions or positional relationships shown in the accompanying drawings, and are only for the convenience of description and simplified description, and do not indicate or imply that the device or element referred to must have a specific orientation, be constructed and operated in a specific orientation, and therefore cannot be understood as a limitation of the present invention. In addition, the terms "first", "second", and "third" are used for descriptive purposes only and cannot be understood as indicating or implying relative importance. Moreover, in the description of the scheme, with the operator as a reference, the direction close to the operator is the proximal end, and the direction away from the operator is the distal end.
[0049] Example 1
[0050] The following is an explanation of the method for determining the validity of the test results of the immune in vitro diagnostic reagent disclosed in the present invention. The inventors have found through research that after eluting the immune complexes of normal detection with an elution solution, since the immune affinity between the specific antibody and the antigen is certain, the proportion of the immune complexes washed away at the same concentration is constant within a certain range. If the detection signal is obtained by combining other methods such as non-specific results, interference from other substances, interference from heterophilic antibodies, etc., its elution ratio will be largely different from the normal antigen-antibody specific results. The specificity of the reaction can be distinguished by this elution ratio (elution percentage), and the validity of the result can be determined accordingly.
[0051] The determination method specifically comprises the following steps:
[0052] S0, perform immunoassay according to a conventional immunoassay method and obtain a first test result, specifically, perform immunoassay according to a fluorescent immunoassay method in a quartz probe mode, and the specific process is as follows
[0053] S01, prepare the detection probe, cleaning solution, biotinylated detection antibody, streptavidin-cyanine dye 5 and detection sample required for immunoassay; the detection probe can be a ready-made detection probe coated with PCT capture antibody, or can be coated on site to prepare the detection probe. The biotinylated detection antibody corresponds to a biotinylated PCT detection antibody.
[0054] S02, cleaning the detection probe with a cleaning solution; during the specific cleaning, the detection probe is sequentially immersed in the PBST cleaning solution in two cleaning holes for two cleanings, and each cleaning time is about 45 seconds.
[0055] S03, after cleaning, immersing the detection probe into the detection sample for a first target reaction time, wherein the first target reaction time is about 180 seconds.
[0056] S04, after taking out the detection probe from the detection sample, wash it with a cleaning solution; during the specific cleaning, immerse the detection probe into the PBST cleaning solution in three cleaning holes in turn and wash it three times, and each cleaning time is about 10 seconds.
[0057] S05, after cleaning, immersing the detection probe in the biotinylated detection antibody for reaction for a second target time, wherein the second target time is about 60 seconds.
[0058] S06, after the detection probe is taken out from the biotinylated detection antibody, it is washed with a washing solution. Specifically, during the washing, the detection probe is sequentially immersed in the PBST washing solution in three washing wells for three washings, and each washing time is about 10 seconds.
[0059] S07, after cleaning, immersing the detection probe in streptavidin-cyanine dye 5 to react for a third target time, wherein the third target time is about 30 seconds.
[0060] S08, after taking out the detection probe from the streptavidin-cyanine dye 5, wash it with a washing solution. Specifically, during washing, the detection probe is immersed in the PBST washing solution in three washing wells in turn and washed three times, and each washing time is about 10 seconds.
[0061] S09, after cleaning, place the detection probe into the reading hole for reading, and obtain the first detection result. Figure 1 The structure and principle shown are read.
[0062] S1, after obtaining the first detection result of the immunoassay, the detection probe subjected to the above immunoassay is eluted with an eluent; the eluent is at least one of PBST buffer, TBST buffer, MES buffer, and glycine buffer, and the pH value of the eluent is between 2 and 8.
[0063] The elution time of the detection probe in the eluent is between 30 and 180 seconds. This is because the inventors found that due to the difference in affinity between different antigens and antibodies, it is crucial to choose the right time. When the elution time is less than 30 seconds, the elution ratio is too low. When the elution time of the detection probe in the eluent exceeds 180 seconds, the elution ratio is too high, which will lead to the inability to distinguish between specific or nonspecific binding, that is, invalid judgment.
[0064] S2, immersing the eluted detection probe into the reading hole, reading it through the reading device, and obtaining the second detection result.
[0065] S3, calculating the elution percentage according to the first test result and the second test result; when specifically calculating, the elution percentage P is calculated according to the following formula:
[0066] P=(Q1-Q2) / Q1%
[0067] Among them, Q1 is the first detection result, and Q2 is the second detection result.
[0068] S4, determining whether the elution percentage is within a threshold range, if so, determining that the test result of the immune in vitro diagnostic reagent is normal; otherwise, determining that the test result of the immune in vitro diagnostic reagent is abnormal.
[0069] The threshold range is preferably between 24.9% and 44.3%. This threshold range is determined by the inventors by comparing the elution percentages of normal samples, HAMA samples, high-concentration hemoglobin interference samples, and heterophilic antibody samples determined according to the above steps S0-S5 and according to a certain standard deviation. The statistical table of data after different test samples are tested according to the above steps S0-S5 is as follows:
[0070]
[0071]
[0072] Table (1): Data statistics of normal samples with different concentrations after testing according to the above steps S0-S5 Table (2): Data statistics of different special samples after testing according to the above steps S0-S5
[0073]
[0074] In the table, F indicates that the test result is abnormal.
[0075] The above-mentioned entire reaction and confirmation process can be achieved by manual operation or by automated equipment. For example, the entire process of fluorescent immunoassay reaction and effectiveness determination can be achieved by the Pylon3D fully automatic immunoassay system or the PylonIRIS high-speed fully automatic immunoassay system produced by Star Child Medical Technology (Shanghai) or (Suzhou) Co., Ltd.
[0076] Example 2
[0077] Compared with the above-mentioned embodiment 1, the main innovation of this embodiment is that the detection probe used in the fluorescent immunoassay is treated with a moisture-proof liquid during the coating process so as to have stronger moisture-proof and humidity-resistant properties.
[0078] The detection probe is processed according to the following steps:
[0079] Step 1, depositing a silane coupling agent on the surface of a quartz probe; uniformly depositing the silane coupling agent on the surface of the pure quartz probe by a known vapor deposition method, wherein the silane coupling agent is, for example, 3-aminopropyltrimethoxysilane, which improves the hydrophobicity of the probe surface, thereby more efficiently adsorbing protein substances, and the amino group (NH2) on the surface can be used as a covalently coupled organic group to covalently couple with the protein.
[0080] Step 2: prepare the phosphate buffer solution, procalcitonin (PCT) antibody solution, blocking solution, primary cleaning solution, secondary cleaning solution and moisture-proof solution required for quartz probe coating.
[0081] The concentration of procalcitonin (PCT) is 20ug / ml. The blocking solution can be a known feasible material, such as BSA blocking solution, which is not limited here. The cleaning solution can be a known feasible material, such as PBST solution, which is not limited here.
[0082] The moisture-proof liquid comprises 0.01-0.1M buffer, 0.01%-0.1% (V / V) surfactant, 0.01%-0.1% (V / V) preservative and 1%-20% (m / v) stabilizer.
[0083] The buffer is mainly used to ensure the pH value of the system, making it acidic, so that the moisture-proof liquid carries a positive charge, thereby protecting the organic groups (such as amino, thiol, etc.) in the silane coupling agent from being neutralized or hydrolyzed. The buffer can be an acetic acid-sodium acetate buffer or an MES buffer, preferably an acetic acid-sodium acetate buffer.
[0084] The acetic acid-sodium acetate buffer keeps the pH value of the moisture-proof liquid at about 4.0 to 6.5. This is because the inventors found that when the pH value exceeds 6.5, the silane adhesive will be hydrolyzed or neutralized, causing its surface to lose hydrophobicity and unable to fix substances such as proteins; and when the pH value is lower than 4.0, it will cause excessive acidity, and the fixed protein substances will be denatured and inactivated. At the same time, when the pH value is lower, for example, when the pH value is greater than 4.0 and less than 5.5, the acetic acid-sodium acetate buffer has a stronger buffering capacity and can better resist interference from most samples, air or moisture.
[0085] The surfactant is mainly used to reduce the surface tension of the quartz probe, form micelles on the surface of the quartz probe, and protect the hydrophobic groups inside the micelles to prevent the immobilized enzymes or protein substances from denaturing. Preferably, the surfactant is at least one of Triton X-100, Triton X-405 and Tween-20, preferably Tween-20, which can increase hydrophilicity and prevent non-specific binding. The inventors have found through research that when the Tween-20 is too little, it cannot resist non-specific binding, and when it is too much, it will affect the binding between proteins.
[0086] The stabilizer is mainly used to keep the immobilized enzymes or proteins relatively stable and prevent them from being denatured or inactivated due to surface treatment measures. The stabilizer is at least one of trehalose, mannitol, and sucrose, preferably sucrose, because sucrose has better water solubility and stability, and forms a coating on the surface of the matrix to isolate the air, thereby protecting the proteins bound to the silane adhesive and preventing them from being oxidized and denatured by air.
[0087] When preparing the moisture-proof liquid, follow the following procedure:
[0088] Step A, prepare sucrose, glacial acetic acid, Tween-20, preservative, purified water and sodium hydroxide solution; wherein, the purity of sucrose is>98%, and the corresponding product of Sigma brand can be used; Tween-20, the corresponding product of Sigma brand can be used; the purity of glacial acetic acid is>99.9995%, and the corresponding product produced by Sinopharm Group can be used; the purity of sodium hydroxide solution is>96%, and AR, the corresponding product produced by Sinopharm Group can be used; Proclin300 (preservative), the corresponding product of Sigma brand can be used.
[0089] Step B, placing a predetermined amount of sucrose in a container, adding predetermined amounts of glacial acetic acid, Tween-20, and a preservative, and then adding purified water to a specified volume to obtain a mixture;
[0090] Step C, stirring the mixture obtained from S2 by a magnetic stirrer;
[0091] Step D, adding sodium hydroxide solution to the stirred mixed solution to adjust the pH of the mixed solution to a target range, and then fixing the volume to a target volume to obtain a moisture-proof liquid.
[0092] Taking the preparation of 1L moisture-proof liquid as an example, the specific components and contents of different formulas are as follows:
[0093]
[0094]
[0095] When configuring, take the configuration process of moisture-proof liquid of formula 1 as an example, and the process is as follows:
[0096] Weigh 150g of sucrose using an electronic balance and put it into a beaker;
[0097] Add 6 mL of glacial acetic acid, 0.5 mL of Tween-20, 0.5 mL of proclin 300 to a beaker, and then add purified water to 900 mL to obtain a mixture.
[0098] After the mixture was stirred and mixed by a magnetic stirrer, the pH value was adjusted to a corresponding range with a 10N NaOH solution, and the volume was fixed to 1 L with a volumetric flask to obtain the moisture-proof liquid.
[0099] The preparation process of the moisture-proof liquid of Formula 2 and Formula 3 is the same as that of the above-mentioned Formula 1, and will not be repeated here.
[0100] Step 3: After all the required materials are prepared, the quartz probe is coated. The corresponding steps are as follows:
[0101] The quartz probes deposited with the silane coupling agent are installed in the probe bracket. The distribution pattern of the quartz probes on the probe bracket is consistent with the hole distribution pattern and hole spacing of the 96-well plate.
[0102] The phosphate buffer solution, PCT antibody solution, blocking solution, primary cleaning solution, secondary cleaning solution and moisture-proof solution for coating were dispensed into 96-well plates at 250 ul each.
[0103] A 96-well plate filled with phosphate buffer solution is fixed on a shaking table, a probe holder is fixed on the shaking table, and the quartz probe on the probe holder is immersed in the phosphate buffer solution of the 96-well plate, and the shaking table is shaken at a set speed for a first target time, and the first target time can be designed as needed, for example, 10 seconds.
[0104] After the shaking table shakes for the first target time, remove the probe holder and the 96-well plate containing phosphate buffer solution from the shaking table; fix the 96-well plate containing PCT antibody solution on the shaking table, fix the probe holder on the shaking table, and immerse the quartz probe on the probe holder in the phosphate buffer solution of the 96-well plate, and shake the shaking table at a set speed for the second target time. The second target time can be designed as needed, preferably between 170-200 seconds, and preferably around 180 seconds.
[0105] After the shaking table shakes for the second target time, remove the probe holder and the 96-well plate containing the PCT antibody solution from the shaking table; fix the 96-well plate containing the blocking solution on the shaking table, fix the probe holder on the shaking table, and immerse the quartz probe on the probe holder in the blocking solution of the 96-well plate, and shake the shaking table at a set speed for the third target time. The third target time can be designed as needed, and is preferably around 60 seconds here.
[0106] After the shaking table has been shaking for the third target time, remove the probe holder and the 96-well plate containing the blocking solution from the shaking table; fix the 96-well plate containing the primary cleaning solution (PBST solution) on the shaking table, fix the probe holder on the shaking table, and immerse the quartz probe on the probe holder in the primary cleaning solution of the 96-well plate, and shake the shaking table at a set speed for the fourth target time. The fourth target time can be designed as needed, and is preferably about 10 seconds here.
[0107] After the shaking table has been shaking for the fourth target time, remove the probe holder and the 96-well plate containing the primary cleaning solution from the shaking table; fix the 96-well plate containing the secondary cleaning solution (PBST solution) on the shaking table, fix the probe holder on the shaking table, and immerse the quartz probe on the probe holder in the secondary cleaning solution of the 96-well plate. The shaking table shakes at a set speed for the fourth target time. The fourth target time can be designed as needed, and is preferably about 10 seconds here.
[0108] After the shaking table has been shaking for the fifth target time, the probe holder and the 96-well plate containing the secondary cleaning solution are removed from the shaking table; the 96-well plate containing the moisture-proof solution is fixed on the shaking table, the probe holder is fixed on the shaking table, and the quartz probe on the probe holder is immersed in the moisture-proof solution of the 96-well plate. The shaking table is shaken at a set speed for the sixth target time. The sixth target time can be designed as needed, preferably between 20-40 seconds, and more preferably 30 seconds. After the processing is completed, the probe holder is removed from the shaking table to complete the coating of the quartz probe.
[0109] Step 4: Dry the coated quartz probe to obtain the detection probe and store it. During drying, take the detection probe out of the probe bracket and dry it at 40° C. for about 4 hours. The drying can be done in a drying oven.
[0110] For the convenience of comparison, the detection probes obtained by coating with ordinary buffer and the detection probes obtained by coating with the above three formulas of moisture-proof liquid were exposed to an environment of about 87% humidity prepared by saturated potassium chloride for about 4 hours, 8 hours, 24 hours, and 48 hours, and then fluorescent immunoassay was performed and the detection fluorescence signals were compared. The specific process and principle of fluorescent immunoassay are the same as the above S0 process, which will not be repeated here.
[0111] After the immunoassay, the differences in the fluorescence signals were analyzed and detected, as shown in the following tables (3), (4), and (5).
[0112] Table (3): Data table of fluorescence signal of immunoassay using two detection probes treated with moisture-proof solution of formula 1 and ordinary buffer solution:
[0113]
[0114]
[0115] Table (4): Data table of fluorescence signal of immunoassay of two detection probes treated with moisture-proof liquid of formula 2 and ordinary buffer solution:
[0116]
[0117]
[0118] Table (5): Data table of fluorescence signal of immunoassay of two detection probes treated with moisture-proof liquid of formula 3 and ordinary buffer solution:
[0119]
[0120] It can be seen from the data in the above Tables (3), (4) and (5) that, compared with the detection probes that have not been treated with moisture-proof liquid, the detection probes that have been treated with moisture-proof liquid and stored in a relatively humid environment, when used in immunoassays, have significantly more detection fluorescence signals read, and the detection results are more effective and more accurate; and the deviation of different detection results is very small and the consistency is high.
[0121] After the detection probe obtained by the coating method of this embodiment is surface-modified by a silane coupling agent, a process of immersing it in a moisture-proof liquid is added during the coating process. Therefore, after the detection probe is dried, the humidity resistance time of the antigen or antibody fixed to the surface of the glass fiber matrix by the silane coupling agent is significantly extended, thereby significantly extending the active life of the antigen or antibody.
[0122] Example 3
[0123] This embodiment discloses a method for determining the validity of the test results of an immune in vitro diagnostic reagent. The method is based on the above-mentioned Pylon 3D fully automatic immunoassay system or Pylon IRIS high-speed fully automatic immunoassay system. The method comprises the following steps:
[0124] S10, controlling the mobile actuator to drive the detection probe to perform immune detection according to a conventional immune detection process and obtain a first detection result; the immune detection process is to drive the test probe to perform detection according to the detection process of S0 above by the mobile actuator, which will not be repeated here.
[0125] S20, controlling the mobile actuator to immerse the detection probe processed in S10 into the elution solution for elution; that is, eluting the detection probe after the first reading.
[0126] S30, controlling the moving actuator to move the eluted detection probe to the reading hole, controlling the reading device to read, and obtaining a second detection result.
[0127] S40, determining the elution percentage according to the second detection result and the first detection result; the specific calculation process is the same as that in Example 1 and will not be described in detail here.
[0128] S50, determining whether the elution percentage is within a preset range; if so, determining that the test result of the immunological in vitro diagnostic reagent is normal; otherwise, determining that the test result of the immunological in vitro diagnostic reagent is abnormal.
[0129] Example 4
[0130] This embodiment discloses a system for determining the validity of the test results of an immune in vitro diagnostic reagent, comprising:
[0131] An immune detection unit, used for controlling the mobile actuator to drive the detection probe to perform immune detection according to a conventional immune detection method and obtain a first detection result;
[0132] An elution unit is used to control the mobile actuator to immerse the detection probe processed by the immunodetection unit into the elution solution for elution;
[0133] A re-reading unit, used to control the moving actuator to move the eluted detection probe to the reading hole, control the reading device to read, and obtain a second detection result;
[0134] a calculation unit, configured to determine an elution percentage according to the second detection result and the first detection result;
[0135] The judging unit is used to judge whether the elution percentage is within a preset range; if so, it is determined that the test result of the immune in vitro diagnostic reagent is normal; otherwise, it is determined that the test result of the immune in vitro diagnostic reagent is abnormal.
[0136] There are many implementation methods of the present invention, and all technical solutions formed by equivalent transformation or equivalent transformation fall within the protection scope of the present invention.
Claims
1. A method for determining the validity of test results of an immune in vitro diagnostic reagent, characterized in that: The steps include: S1, after obtaining the first detection result of the immunoassay, the detection probe that has undergone the immunoassay is eluted with an eluent; the elution time of the detection probe in the eluent is between 30 and 180 seconds; S2, immersing the eluted detection probe into a reading hole, reading the result through a reading device, and obtaining a second detection result; S3, calculating the elution percentage according to the first test result and the second test result; S4, determining whether the elution percentage is within the threshold range, if so, determining that the test result of the immune in vitro diagnostic reagent is normal; otherwise, determining that the test result of the immune in vitro diagnostic reagent is abnormal; The first detection result is obtained according to the following steps: S01, preparing the detection probe, cleaning solution, biotinylated detection antibody, streptavidin-cyanine dye 5 and detection sample required for immunoassay; S02, cleaning the detection probe with a cleaning solution; S03, after cleaning, immersing the detection probe into the detection sample to react for a first target time; S04, taking out the detection probe from the detection sample and cleaning it with a cleaning solution; S05, after washing, immersing the detection probe in the biotinylated detection antibody to react for a second target time; S06, removing the detection probe from the biotinylated detection antibody and washing it with a washing solution; S07, after washing, immersing the detection probe in streptavidin-cyanine dye 5 to react for a third target time; S08, taking out the detection probe from the streptavidin-cyanine dye 5 and washing it with a washing solution; S09, after cleaning, placing the detection probe into the reading hole for reading, and obtaining the first detection result; The detection probe is treated with a moisture-proof liquid during the coating process; The moisture-proof liquid comprises a buffer solution of 0.01 to 0.1 M, a surfactant of 0.01% to 0.1% V / V, a preservative of 0.01% to 0.1% V / V and a stabilizer of 1% to 20% m / V, and the pH value of the moisture-proof liquid is maintained between 4.0 and 6.5; the buffer solution is an acetic acid-sodium acetate buffer solution or an MES buffer solution; the surfactant is at least one of Triton X-100, Triton X-405 and Tween-20; and the stabilizer is at least one of trehalose, mannitol and sucrose.
2. The method according to claim 1, characterized in that: The eluent is at least one of PBST buffer, TBST buffer, MES buffer and glycine buffer.
3. The method according to claim 2, characterized in that: The pH value of the eluent is between 2 and 8.
4. The method according to claim 1, characterized in that: The elution percentage P is calculated according to the following formula: P=(Q1-Q2) / Q1% Among them, Q1 is the first detection result, and Q2 is the second detection result.
5. The method according to claim 1, characterized in that: The threshold range is between 24.9% and 44.3%.
6. A method for determining the validity of test results of an in vitro diagnostic reagent for immune system, characterized in that: The steps include: S10, controlling the mobile actuator to drive the detection probe to perform immune detection according to a conventional immune detection process and obtain a first detection result; The first detection result is obtained according to the following steps: S01, preparing the detection probe, cleaning solution, biotinylated detection antibody, streptavidin-cyanine dye 5 and detection sample required for immunoassay; S02, cleaning the detection probe with a cleaning solution; S03, after cleaning, immersing the detection probe into the detection sample to react for a first target time; S04, taking out the detection probe from the detection sample and cleaning it with a cleaning solution; S05, after washing, immersing the detection probe in the biotinylated detection antibody to react for a second target time; S06, removing the detection probe from the biotinylated detection antibody and washing it with a washing solution; S07, after washing, immersing the detection probe in streptavidin-cyanine dye 5 to react for a third target time; S08, taking out the detection probe from the streptavidin-cyanine dye 5 and washing it with a washing solution; S09, after cleaning, placing the detection probe into the reading hole for reading, and obtaining the first detection result; The detection probe is treated with a moisture-proof liquid during the coating process; The moisture-proof liquid comprises 0.01-0.1M buffer, 0.01%-0.1%V / V surfactant, 0.01%-0.1%V / V preservative and 1%-20%m / V stabilizer, and the pH value of the moisture-proof liquid is maintained between 4.0 and 6.5; the buffer is acetic acid-sodium acetate buffer or MES buffer; the surfactant is at least one of Triton X-100, Triton X-405 and Tween-20; the stabilizer is at least one of trehalose, mannitol and sucrose; S20, controlling the mobile actuator to immerse the detection probe processed in S10 into the eluent for elution; the elution time of the detection probe in the eluent is between 30 and 180 seconds; S30, controlling the moving actuator to move the eluted detection probe to the reading hole, controlling the reading device to read, and obtaining a second detection result; S40, determining an elution percentage according to the second detection result and the first detection result; S50, determining whether the elution percentage is within a preset range; If so, confirm that the test results of the immune in vitro diagnostic reagent are normal; Otherwise, it is determined that the test result of the immune in vitro diagnostic reagent is abnormal.
7. A system for determining the validity of test results of in vitro diagnostic reagents for immune system, characterized in that: include An immune detection unit, used for controlling the mobile actuator to drive the detection probe to perform immune detection according to a conventional immune detection method and obtain a first detection result; An elution unit is used to control the mobile actuator to immerse the detection probe processed by the immune detection unit into the elution solution for elution; the elution time of the detection probe in the elution solution is between 30 and 180 seconds; A re-reading unit, used to control the moving actuator to move the eluted detection probe to the reading hole, control the reading device to read, and obtain a second detection result; a calculation unit, configured to determine an elution percentage according to the second detection result and the first detection result; A judgment unit, used to judge whether the elution percentage is within a preset range; if so, determining that the test result of the immune in vitro diagnostic reagent is normal; otherwise, determining that the test result of the immune in vitro diagnostic reagent is abnormal; The first detection result is obtained according to the following steps: S01, preparing the detection probe, cleaning solution, biotinylated detection antibody, streptavidin-cyanine dye 5 and detection sample required for immunoassay; S02, cleaning the detection probe with a cleaning solution; S03, after cleaning, immersing the detection probe into the detection sample to react for a first target time; S04, taking out the detection probe from the detection sample and cleaning it with a cleaning solution; S05, after washing, immersing the detection probe in the biotinylated detection antibody to react for a second target time; S06, removing the detection probe from the biotinylated detection antibody and washing it with a washing solution; S07, after washing, immersing the detection probe in streptavidin-cyanine dye 5 to react for a third target time; S08, taking out the detection probe from the streptavidin-cyanine dye 5 and washing it with a washing solution; S09, after cleaning, placing the detection probe into the reading hole for reading, and obtaining the first detection result; The detection probe is treated with a moisture-proof liquid during the coating process; The moisture-proof liquid comprises a buffer solution of 0.01 to 0.1 M, a surfactant of 0.01% to 0.1% V / V, a preservative of 0.01% to 0.1% V / V and a stabilizer of 1% to 20% m / V, and the pH value of the moisture-proof liquid is maintained between 4.0 and 6.5; the buffer solution is an acetic acid-sodium acetate buffer solution or an MES buffer solution; the surfactant is at least one of Triton X-100, Triton X-405 and Tween-20; and the stabilizer is at least one of trehalose, mannitol and sucrose.
